生理药代动力学模型在EGFR-TKI精准治疗中的应用进展

http://www.100md.com 2025年6月2日中国药房 2025年第8期

奥希替尼,特殊人群,吉非

     中图分类号R969.1；R969.3 文献标志码A 文章编号1001-0408(2025)08-1013-06

    DOI 10.6039/j.issn.1001-0408.2025.08.22

    Advances in the application of physiologically-based pharmacokinetic model in EGFR-TKI precision therapy

    YANG Yingying'，SHAO Jiaqi'2，XIANG Qiulin'，LI Guoxing'，YU Xian'(1. Phase I Clinical Trial Center， the Second Ailiated Hospital of Chongqing Medical University， Chongqing 400o60，China； 2.College of Pharmacy，Chongqing Medical University， Chongqing 400016，China)

    ABSTRACTEpidermalgrowthfactorreceptor-tyrosinekinase inhibitor(EGFR-TKI)representaclassof small-molecule targeted therapeuticsforoncologytreatmentandserveafrst-linetherapyforadvancednonsmallcellungcancer(NSCLC)withEGFRsensitivemutations，withrepresentativeagentsincludinggefitinib，dacomitinib，andosimertinibInclinicalpractice，dose adjustmentofEGFR-TKImay be required forcancer patients under specialcircumstances suchas drug combinationsorhepatic/ renalmpairment.Physiologically-basedphamacokinetic(PBPK)model，capableofpredicting pharmacokinetic(PK)procesesin humans，hasemergedasavitaltolforclinicaldoseptimizationThiarticlesortsthemodelingmethodologiesworkflowsand commonly usedsoftwaretoosforPBPKmodelandsummarizesthecurrent applicationsofPBPKmodelinEGFR-KIprecision therapyasofJune 30 ......

百拇医药网 http://www.100md.com/html/paper/1001-0408/2025/08/022.htm

您现在查看是摘要页，全文长 25204 字符。